Back

Galectin-3 inhibitors as novel antithrombotic drugs with almost no bleeding risk: wishful thinking or a realistic vision?

European Heart Journal

8 April 2022
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE Acute Coronary Syndromes HEART FAILURE Chronic Heart Failure BASIC SCIENCE Pharmacology and Pharmacotherapy

Contributors

Kai Jakobs
Kai Jakobs

Author

Ursula Rauch
Ursula Rauch

Author

Charite University Hospital Berlin , Germany

You may be interested in
thumbnail
Congress Presentation
Role of Galectin-3 in resident macrophages and effects on atherosclerosis
30 August 2024
thumbnail
Congress Session
How can targeting FXI(a) advance antithrombotic therapy for stroke prevention?
27 August 2023
thumbnail
Congress Presentation
Influence of therapy in patients with CAD and type 2 diabetes on inflamation biomarkers P-selectin and Galectin-3 changes
20 May 2023
thumbnail
Congress Presentation
Galectin 3 : possible tool for early detection of LV diastolic dysfunction in asymptomatic survivors of childhood, adolescent and young adult cancer
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources